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Abstract
Background: Familial dysautonomia (FD) is a hereditary neuropathy caused by mutations in the IKBKAP gene, the most
common of which results in variable tissue-specific mRNA splicing with skipping of exon 20. Defective splicing is especially
severe in nervous tissue, leading to incomplete development and progressive degeneration of sensory and autonomic
neurons. The specificity of neuron loss in FD is poorly understood due to the lack of an appropriate model system. To better
understand and modelize the molecular mechanisms of IKBKAP mRNA splicing, we collected human olfactory ecto-
mesenchymal stem cells (hOE-MSC) from FD patients. hOE-MSCs have a pluripotent ability to differentiate into various cell
lineages, including neurons and glial cells.
Methodology/Principal Findings: We confirmed IKBKAP mRNA alternative splicing in FD hOE-MSCs and identified 2 novel
spliced isoforms also present in control cells. We observed a significant lower expression of both IKBKAP transcript and IKAP/
hELP1 protein in FD cells resulting from the degradation of the transcript isoform skipping exon 20. We localized IKAP/
hELP1 in different cell compartments, including the nucleus, which supports multiple roles for that protein. We also
investigated cellular pathways altered in FD, at the genome-wide level, and confirmed that cell migration and cytoskeleton
reorganization were among the processes altered in FD. Indeed, FD hOE-MSCs exhibit impaired migration compared to
control cells. Moreover, we showed that kinetin improved exon 20 inclusion and restores a normal level of IKAP/hELP1 in FD
hOE-MSCs. Furthermore, we were able to modify the IKBKAP splicing ratio in FD hOE-MSCs, increasing or reducing the WT
(exon 20 inclusion):MU (exon 20 skipping) ratio respectively, either by producing free-floating spheres, or by inducing cells
into neural differentiation.
Conclusions/Significance: hOE-MSCs isolated from FD patients represent a new approach for modeling FD to better
understand genetic expression and possible therapeutic approaches. This model could also be applied to other neurological
genetic diseases.
Citation: Boone N, Loriod B, Bergon A, Sbai O, Formisano-Tre ´ziny C, et al. (2010) Olfactory Stem Cells, a New Cellular Model for Studying Molecular Mechanisms
Underlying Familial Dysautonomia. PLoS ONE 5(12): e15590. doi:10.1371/journal.pone.0015590
Editor: Carlo Gaetano, Istituto Dermopatico dell’Immacolata, Italy
Received September 2, 2010; Accepted November 13, 2010; Published December 20, 2010
Copyright:  2010 Boone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors thank the Association Franc ¸aise de Recherche contre les Myopathies (AFM) for supporting their work. NB was supported by a PhD
fellowship from the Ministe `re de l’Education Nationale, de la Recherche et de la Technologie (MENRT). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: el-cherif.ibrahim@univmed.fr
Introduction
Familial dysautonomia (FD, Riley-Day syndrome, hereditary
sensory and autonomic neuropathy type III, MIM 223900) is an
autosomal recessive genetic disorder that occurs in 1:3600 live
births with a carrier frequency of 1 in 30 in the Ashkenazi Jewish
population. The disease is characterized by incomplete develop-
ment and the progressive depletion of autonomic and sensory
neurons [1–3] resulting in variable symptoms including: insensi-
tivity to pain, lack of overflow tearing, inappropriate blood
pressure control manifested as orthostatic hypotension and
episodic hypertension, poor oral coordination resulting in poor
feeding and swallowing, and gastrointestinal dysmotility [4]. No
cure is available for this disorder and treatment is aimed at
controlling symptoms and avoiding complications.
FD is caused by mutations in the IKBKAP gene which encodes a
protein termed IKAP/hELP1 [5,6]. The most prevalent mutation,
is a splice mutation; the T-to-C transition in position 6 of the 59
splice site (59ss) of intron 20 (IVS20
+6TRC) of this gene. All FD cases
have at least one copy of this mutation; .99.5% are homozygous
[5–7]. This mutation leads to variable, tissue-specific skipping of
exon 20 of IKBKAP mRNA, with the central and peripheral nervous
system more prone to complete skipping than others tissues, which
leads to reduced IKAP/hELP1 protein levels [8].
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15590Although the exact function of the IKAP/hELP1 protein is not
clearly understood, researchers have identified IKAP/hELP1 as the
scaffold protein required to assemble a well conserved six-protein
complex (ELP1-6) called the holo-Elongator complex that possess
histone acetyltransferase activity directed against histone H3 and
H4 in vitro [9]. IKAP/hElongator is recruited to the transcribed
regions of some human genes essentially involved in actin
cytoskeleton regulation and cell motility migration [10]. This role
may underlie a cell motility deficiency in FD neurons because of
impaired transcriptional elongation of some genes coding for
proteins involved in cell migration. Indeed, one study found that
mouse neurons defective in Elongator exhibit reduced levels of
acetylated a-tubulin, causing defects in radial migration and
branching of cortical projections neurons [11]. Another study
showed that Caenorhabditis elegans Elongator complex is required for
correct acetylation of microtubules and neuronal development [12].
IKAP/hELP1 protein is also involved in other cellular processes,
including tRNA modifications [13–15], exocytosis [16], and zygotic
paternal genome demethylation [17]. Recently, its homolog in fly
(D-elp1) has also been suggested to be involved in RNA interference
through a RNA-dependent RNA polymerase activity [18].
To better understand the molecular mechanisms leading to
aberrant splicing of IKBKAP mRNA in FD, creation of model
systems recapitulating the pathological development of neural cells
is required. Because IKBKAP gene knock out causes embryonic
lethality [19], an animal model that exhibits the major phenotypic
characteristics observed in FD humans has not yet been
established. However, a humanized IKBKAP transgenic mouse
model for FD has been created [20], that reproduces the tissue-
specific splicing of IKBKAP mRNA in nervous tissues. Such a
model is a notable progress in the comprehension of this complex
rare disease and offers a potential system for testing therapeutic
agents. However, transgenic animals do not reproduce phenotypic
features of FD as they maintain normal development. Alterna-
tively, FD patient fibroblasts are an informative model of mRNA
splicing regulation. However, a recent study suggests that IKAP/
hELP1 expression is much higher in neurons compared to
fibroblasts [21], and fibroblasts do not exhibit the same ratio of
IKBKAP exon 20 including:exon 20 skipping transcripts (named
WT:MU respectively for simplicity) as observed in nervous system-
derived tissues [8]. This finding narrows the understanding of
disease mechanisms in a neural context. Finally, generation of
neural cells through the production of induced pluripotent stem
(iPS) cell from FD fibroblasts has been recently established [22].
Neural cells derived from iPS cells have potential to be used for
studies of neuropathologies [23]. However, the labor intensive
reprogramming required to induce iPS cells erases the develop-
mentally relevant epigenetic signature specific to the disease state.
As a consequence, some important information may be lost
impeding recreation of an accurate disease model. The demon-
stration that fibroblasts can be converted directly into neurons,
without an initial reprogramming, as recently evidenced in mouse
[24], is very attractive. Nevertheless, during their reprogramming,
human iPS cells do not pass through the normal stages of
embryonic development that human ES cells undergo. Although
both stem cell types share a common transcriptional signature, a
subset of genetic profiles found in human iPS cells suggests
retention of transcriptional and epigenetic memory related to their
tissue of origin, which can substantially affect their potential to
differentiate into different cell types [25–27]. Thus, cells collected
from primary sources that have been subjected to environmental
signals appropriate for the pathological specificity of the targeted
disease are likely important to mirror the biology of diseased
human neural cells.
Our aim is to understand what mechanisms drive IKBKAP
mRNA splicing to the almost exclusive production of aberrant
transcripts (MU) in neuronal cells. Here we demonstrate the
potential of human olfactory ecto-mesenchymal stem cells (hOE-
MSCs) to model this aspect in FD. Indeed, neurogenesis occurs
throughout adult life in the olfactory mucosa, due to the presence
of resident multipotent stem cells giving rise to olfactory neurons in
vivo [28]. hOE-MSCs can be grown into neurospheres, that are
multipotent, and differentiate in vitro into neurons, astrocytes, and
oligodendrocytes as well as other cell types [29,30]. Isolated from
patients, cultures of hOE-MSCs provide potential models for
genetically determined neuropsychiatric diseases [31–33], and
stand as an interesting human model to investigate gene networks
and cellular pathways altered in disease like FD. For example, cell
migration defects have been observed in cells lacking normal
expression of IKAP/hELP1 [10,11,22,34], and we show here that
FD hOE-MSCs exhibit impaired migration compared to control
cells. Additionally, hOE-MSCs are an appropriate model for
validating the potency of therapeutic agents such as kinetin, a
cytokinin that has been shown to increase IKBKAP mRNA and
protein expression in FD cell lines and in vivo models [20,22,35,36]
as well as in leukocytes of healthy carriers of the FD mutation [37].
Results
FD hOE-MSCs express stem cell, glial and immature
neuronal markers
To establish a human cellular model of FD, we collected 4
olfactory mucosa biopsies from homozygous patients for the
IVS20
+6TRC FD mutation. As previously demonstrated with
control biopsies [30], after about 2 weeks of culture, the
microscopic examination of the tissue crushed under a glass
coverslip revealed stem cell proliferation (Figure 1A and 1B). After
reaching confluency in a 4-well plate, the cells attached to the glass
coverslip were further expanded by transfer into a 6-well plate
(Figure 1C). Like control hOE-MSCs, we observed that FD hOE-
MSCs could be cultured for long periods (at least 15 cycles of
trypsin/EDTA treatment and expansion on larger plastic surface)
with a doubling time of about 30–48 h. When subjected to
immunostaining, all hOE-MSCs derived from control and FD
biopsies express the neural stem cell–specific marker nestin
(Figure 1D and 1E) and the immature neuronal marker b-III
tubulin (Figure 1F and 1G) in the same proportions (Figure 1H
and 1I). A comparatively low GFAP staining was observed in every
hOE-MSCs (Figure 1J and 1K). In addition, cells were negative for
a mature neuronal marker, MAP2 (Figure 1L and 1M). This
analysis suggests that both control and FD hOE-MSCs display
properties of neuroglial progenitor cells.
Expression of IKBKAP transcripts is dramatically reduced
in FD hOE-MSCs
IKBKAP mRNA expression was investigated in cultures of 5
controls and 4 FD hOE-MSCs at early (P1, P2) and later cell
passages (P5, P9). A semi quantitative RT-PCR analysis revealed
that, while control hOE-MSCs expressed exclusively the WT
mRNA transcript (Figure 2A, left panel), FD hOE-MSCs
expressed the WT but also the MU transcript (Figure 2A, right
panel). We also demonstrated that long time culture conditions
and trypsin-EDTA mediated cell passages did not affect the
IKBKAP gene expression pattern. In order to more accurately
determine the level of expression of IKBKAP alternative transcripts,
we designed primers, probes and plasmid calibrators to perform
absolute quantification using quantitative real-time RT-PCR (RT-
qPCR) on the same samples. Strikingly, WT transcripts were
OE-MSCs as a Model for FD
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hOE-MSCs (Figure 2B). In addition, WT and MU transcripts
were present in nearly equal amounts in FD hOE-MSCs
(Figure 2B, right graph). Furthermore, the total amount of
IKBKAP transcripts in FD (WT+MU) remains 3 to 5 times less
abundant than WT in controls, which suggests a defect in IKBKAP
transcription and/or mRNA stability. In FD cells, the differential
expression of IKBKAP transcripts was also correlated to a reduced
expression of IKAP/hELP1 protein in FD, when compared to
controls, as revealed by western blot analysis (Figure 2C). Since
MU transcripts contain a premature stop codon that may activate
the nonsense-mediated mRNA decay (NMD) pathway, we wanted
to confirm whether this pathway is responsible for the lower
IKBKAP transcripts expression in FD cells. Thus, we tested
cycloheximide, a protein synthesis inhibitor which also inhibits
NMD. Indeed, FD cells preincubated for 6 h with cycloheximide
exhibited a stabilization of the MU transcript as evidenced by
semi-quantitative RT-PCR (Figure 2D, left panel). To accurately
determine the level of WT and MU IKBKAP transcripts in these
samples, absolute RT-qPCR analysis was performed (Figure 2D,
right panel). The results clearly demonstrated that the WT:MU
ratio decreases when mRNA surveillance is inhibited. Thus, a
Figure 1. hOE-MSCs display characteristics of immature neuroglial cells. A, lamina propria (dark) from an FD olfactory mucosa biopsy was
placed under a glass coverslip to initiate stem cell proliferation. Area delimited by a black square is enlarged in B. C, after transfer in a 6-well plate,
cells attached to the coverslip (arrow) proliferated and colonized the complete area of the well. (D–M), Immunofluorescence stainings of both control
(CTRL) and FD hOE-MSCs are positive for nestin (D, E), b-III tubulin (F,G) with similar expression levels (H, I) while slightly positive for GFAP (J,K) and
negative for MAP2 (L, M). Green represents Alexa fluor-488, red Alexa Fluor-594. Nuclei (blue) were stained with Hoechst blue. Scale bars represent
50 mm.
doi:10.1371/journal.pone.0015590.g001
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NMD pathway resulting in much less IKBKAP transcripts and
IKAP/hELP1 protein in FD compared to control cells.
Heterogeneous IKAP/hELP1 distribution in hOE-MSCs
Since the localization of IKAP/hELP1 remains controversial
and is important to understand protein functions, we stained both
control and FD hOE-MSCs with the monoclonal antibody
directed against IKAP/hELP1 and previously used for detecting
the protein by western blot analysis. In control cells, confocal
imaging revealed a weak and diffuse signal with a dominant
cytoplasmic staining within the perinuclear area. We could also
detect the presence of IKAP/hELP1 in the nucleus of hOE-MSCs
(Figure 3A–C). Significantly, FD hOE-MSCs exhibit a weaker
anti-IKAP/hELP1 immunofluorescence staining compared to
control cells, with a similar distribution of the staining
(Figure 3D–F). Therefore, collectively, our results are in agreement
with a wide distribution of IKAP/hELP1, including a much lower
IKAP/hELP1 staining in FD hOE-MSCs, in agreement with RT-
qPCR and western blot analysis.
Transcriptome analysis identified fifty dysregulated
genes
It is widely accepted that culture conditions alone may exert
effects on gene expression, resulting in experimental inconsisten-
cies [38,39]. Thus, to investigate the involvement of candidate
disease mechanisms in FD and to test whether differences in gene
expression are stably imprinted in FD compared to control hOE-
Figure 2. Expression of IKBKAP transcripts and IKAP/hELP1 protein in hOE-MSCs. A, agarose gel electrophoresis of end-point RT-PCR
products showing both WT and MU transcripts of IKBKAP gene for control (left panel) and FD hOE-MSCs (right panel) at cell passage 1,2,5,9. B, graph
of the mean level of expression of IKBKAP alternative transcripts in control (left panel) and FD hOE-MSCs (right panel) at cell passages 1,2,5,9,
determined by absolute RT-qPCR. ABL1 was used as a reference gene for normalization. Error barrs denote standard error. C, western blot analysis of
total lysate from 4 controls and 4 FD hOE-MSCs using monoclonal anti-IKAP/hELP1 antibody (upper panel). Anti-b-actin was included to show equal
loading (lower panel). D, NMD pathway was blocked by the translation inhibitor cycloheximide and results in an elevated expression of MU
transcripts in FD cells (agarose gel electrophoresis, left panel). Results are confirmed with absolute qPCR normalized with ABL1 (right panel).
doi:10.1371/journal.pone.0015590.g002
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(P1, P2) and later (P5, P9) cell passages with the same samples used
to quantify IKBKAP transcripts. Among the 8,780 cDNA
represented on the microarray, 46 were significantly decreased
and only 4 increased in FD hOE-MSCs, when compared to
control hOE-MSCs (fold-change.1.4-fold; p-value,6.10
3,
Table 1 and Table S1), considering a false discovery rate (FDR)
of 3% (Figure S1). Notably, the biological processes and the
signaling pathways most significantly targeted by the effectors on
our list were actin cytoskeleton organization, cell growth, and
apoptosis (Table 1). More specifically, we identified 10 genes
(Table 1 and Table S1) that also exhibited a significant
dysregulated expression in previous microarray studies [10,22].
Interestingly, 2 genes, PMEPA1 and GSN (encoding TMEPAI and
gelsolin, respectively), involved in cell growth and cytoskeleton
organization, respectively, were dysregulated in both the IKBKAP
RNAi and FD iPS cell studies.
In order to assess the robustness of our microarray analysis, RT-
qPCR analysis was performed, on independent RNAs extracted
from 4 control and 4 FD hOE-MSCs harvested at the second,
fourth, and seventh cell passage. Since gene expression quantifi-
cation using RT-qPCR requires a steady reference gene, we
selected three genes frequently used for normalization of the data,
ABL1, RPLP0, and HPRT1. We confirmed that PMEPA1
(Figure 4A), the most dysregulated gene on the microarray, and
S100A16 (Figure 4B), were significantly underexpressed in FD
samples. The expression pattern of these two candidate genes was
essentially identical at all passages with the 3 reference genes,
which demonstrates the validity and reliability of the array data.
FD OE-MSCs migration is altered compared to controls
To explore the functional consequence of a down-regulated
expression of genes involved in cell migration in FD hOE-MSCs
compared to control cells, we used the Boyden’s chamber assay.
After comparing the migration pattern of 3 control and 3 FD
hOE-MSCs in serum medium and serum-free medium (ITS), we
determined that FD cells invasion is significantly reduced
compared to control cells both in serum and in ITS medium
(Figure 5).
Confirmed down-expression of first and final IKBKAP
exons in FD hOE-MSCs
Since we and others [22,40] did not detect IKBKAP among the
significantly down-regulated transcripts in FD compared to
control samples, we asked whether this discrepancy could be
due to a lack of sensitivity of microarray compared to RT-qPCR.
For this purpose, we decided to analyze IKBKAP levels of
expression by investigating other exons distal from IKBKAP exon
20. By looking at the beginning of IKBKAP transcript, we
identified a second event of alternative splicing. After amplifying
transcripts from exon 1 to exon 5, we obtained 2 PCR products
(Figure 6B, upper panel). The sequencing of the less abundant
and shorter PCR product revealed the use of an alternative 39ss
within IKBKAP exon 2, which is shortened of 145 nt (Figure 6A,
left schematic). Accordingly, the loss of the ATG start codon
located within the 59 end of exon 2 can potentially induce the use
of an alternative ATG start codon (in exon 4), resulting in the
synthesis of a putative 114 amino acid-truncated IKAP/hELP1
protein (Figure 6D).
Figure 3. IKAP/hELP1 distribution in hOE-MSCs. Anti-IKAP/hELP1 immunofluorescence staining in control (A, B, C), FD hOE-MSCs (D, E, F), andFD
hOE-MSCs treated with 100 mM kinetin for 24h (G, H, I). The primary antibody used is a mouse monoclonal anti-IKAP/hELP1. Scale bars represent 20 mm.
doi:10.1371/journal.pone.0015590.g003
OE-MSCs as a Model for FD
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sequence, again we observed a third alternative splicing event. The
amplification from exon 33 to exon previously numbered exon 36
(and now called exon 37) revealed 2 products (Figure 6B, middle
panel). The sequencing of the barely detectable and longer PCR
product revealed the inclusion of an additional exon (Figure 6A,
right schematic). This exon inclusion also induced a frameshift and
resulted in a premature stop codon whose relative location may
Table 1. Most dysregulated genes in FD hOE-MSCs are involved in seven over-represented cellular processes.
Gene Clone ID FC p-value Biological process Studies
Actin cytoskeleton reorganization p=0.000275
GSN 246170 21.91 0.00124 actin cytoskeleton reorganization *1 *2
MYO9B 279085 21.70 0.00144 actin cytoskeleton remodeling
MYPN 325601 21.52 0.00131 sarcomere organization through nebulin and a-actinin interactions
DSTN 149199 21.48 0.00017 actin filament depolymerization
CORO2B 547561 21.44 0.00079 neuronal actin structure reorganization
SLC9A3R2 155467 2.42 0.00034 adaptor of ion channels and receptors to the actin cytoskeleton *1
Regulation of apoptosis p=0.00203
CHEK2 1893020 22.20 0.00007 cell cycle arrest and apoptosis in response to DNA damage *1
ZMAT3 525407 21.78 0.00251 positive regulation of p-53-mediated apoptosis
TNFSF10 713945 21.75 0.00041 induction of apoptosis by activation of caspase activity *2
PARP3 436086 21.60 0.00004 positive regulation of apoptosis- maintenance of genomic stability
Transport p=0.00224
ABCG5 121977 21.59 0.00089 cholesterol transport in and out of the enterocytes
SLC35E1 487960 21.55 0.00086 monosaccharide transport
SLC22A6 36482 21.52 0.00050 a-ketoglutarate transmembrane transporter activity
SFXN2 757192 21.45 0.00021 iron transport
Cell proliferation p=0.00552
APOE 1870594 21.68 0.00028 cell proliferation-regulation of neurite extension *1
CD22 284220 21.58 0.00032 B cell proliferation
CD38 123264 21.54 0.00074 B cell proliferation
GBA 757264 21.53 0.00012 cell proliferation-ceramide metabolic process
SERINC2 149995 1.84 0.00014 cell proliferation
Regulation of cell growth and cell cyle p=0,0091
PMEPA1 366599 24.92 0.00585 EGF receptor signaling pathway - negative regulation of cell growth *1 *2
STRBP 669157 21.75 0.00007 regulation of cell growth
INO80B 323554 21.63 0.00104 growth induction and cell cycle arrest at the G1 phase
S100A16 739851 21.55 0.00012 regulation of cell cycle progression *1
CDIPT 306047 21.49 0.00088 regulation of cell growth
Nervous system process p=0,0302
LRCH1 683580 23.62 0.00080 long-term memory and learning - signal transduction
KCNT2 38677 22.06 0.00010 synaptic transmission mediated by K (+) channels
NUMBL 1855110 21.61 0.00118 Notch signaling pathway inhibition - cerebral cortex morphogenesis
DULLARD 346368 21.53 0.00198 Nuclear organization-negative regulation of BMP signaling
Proteolysis p=0,0334
FBXL15 166240 21.71 0.00130 ubiquitin-dependent protein catabolic process
WSB1 298983 21.61 0.00123 ubiquitination and proteosomal degradation of target proteins
PCSK7 241130 21.53 0.00155 proteolysis- ubiquitous endoprotease activity
RNF115 471834 21.42 0.00067 proteolysis- vesicle-mediated transport - vesicle traffic
MMP27 767086 21.35 0.00067 proteolysis of fibronectin, laminin, gelatins and/or collagens
Clone ID represents the number assigned to the original clones produced by the I.M.A.G.E Consortium. FC=Fold change, and p-values were calculated by SAM analysis
as described in Methods. This list of genes was annotated with the Explain
TM System from Biobase. 7 majors processes are overrepresented in our list of genes, and, for
each process, p-values were calculated and adjusted by the Bonferroni correction. The last column indicates the genes that were also found to be significantly
dysregulated in 2 previous FD studies.
*1=Lee et al. 2009.
*2=Close et al. 2006.
doi:10.1371/journal.pone.0015590.t001
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exon 36 inclusion with specific primers (Figure 6B, lower panel).
Both new alternative splicing events we described were also
observed in others cell types (fibroblasts, HeLa, peripheral
mononuclear cells, data not shown) and we decided to focus on
the two major splicing events, full exon 2 inclusion and exon 36
skipping. We derived the tools (plasmids, primers, probes) to
perform absolute quantification of full-length exon 2 inclusion and
exon 36 skipping by RT-qPCR on samples from 4 controls and 4
FD hOE-MSC cultures. Similar underexpression of IKBKAP
transcripts (WT+MU) was observed in FD cells compared to
control cells, regardless of the exon investigated (Figure 6C). Thus,
these results confirmed a decreased level of IKBKAP transcripts
(WT+MU) in FD cells.
In addition, we tested for the stability of exon 36-containing
transcripts after cycloheximide treatment. Absolute RT-qPCR
analysis revealed that the exon 36 skipping : exon 36 inclusion
ratio decreases when NMD pathway is inhibited (Figure S2),
suggesting that transcripts including exon 36 are degraded through
NMD in FD, as well as in control OE-MSCs (data not shown).
Kinetin treatment corrects aberrant IKBKAP pre-mRNA
splicing
Our next goal was to assess whether the production of both WT
and MU IKBKAP mRNAs can be modulated in our model. In
previous studies, one compound, kinetin (6-furfurylaminopurine)
was found to correct IKBKAP splicing and increase IKAP/hELP1
production in FD cells [35]. We tested whether this drug could
also modify the splicing defect of IKBKAP in FD hOE-MSC cells.
For this purpose, we used increasing concentrations of kinetin (25
to 200 mM) on a FD hOE-MSCs culture for 72 h. As expected,
after semi-quantitative RT-PCR, we observed a significant
decrease of MU transcript compared to non-treated cells on
agarose gel electrophoresis (Figure 7A). The level of IKBKAP
mRNA splicing correction increased proportionally to the
concentration of kinetin, and the MU transcript almost vanished
at 100 mM. The dose-dependent action of kinetin on increasing
WT:MU ratio was confirmed by RT-qPCR analysis (Figure 7B). A
similar finding was observed when IKAP/hELP1 proteins were
detected by western blot analysis (Figure 7C). Accordingly, when
FD hOE-MSC were incubated with 100 mM kinetin for 24 h, we
observed a major increase of anti-IKAP/hELP1 staining, in
cytoplasmic as well as in nuclear areas (Figure 3G–I). However,
the same kinetin treatment could not rescue the migration defect
observed in FD hOE-MSCs with the Boyden’s chamber assay
(Figure 5).
In order to determine how fast kinetin modulates IKBKAP
mRNA splicing, we performed a time-course experiment with a
constant concentration of 80 mM over 24 h. After performing
semi-quantitative RT-PCR analysis, the first significant increase of
WT:MU ratio was seen after 24 h of kinetin treatment (Figure 7D).
Figure 4. Relative levels of expression of PMEPA1 and S100A16
transcripts determined by RT-qPCR. RT-qPCR using total RNAs
extracted from 4 controls and 4 FD hOE-MSCs at cell passages 2, 4 and
7. Histograms represent the mean value of PMEPA1 (A) and S100A16 (B)
transcript expression level, relative to 3 reference genes ABL1, HPRT1,
and RPLP0 in control (grey) and FD samples (black). Error bars denote
standard errors. (* P,0.05; ** P,0,01, *** P,0,001 using two-tailed
Student’s test).
doi:10.1371/journal.pone.0015590.g004
Figure 5. FD hOE-MSCs demonstrate reduced migration. Cell
invasion in 3 different controls and 3 different FD hOE-MSCs was
studied using Boyden chamber assay. Cells (3610
4) were added to the
upper chamber in serum medium, serum-free medium (ITS), or ITS
supplemented with 100 mM kinetin. Cell invasion was mesured after
24 h. Results are shown as the average 6 SEM of the number of cells
per microscopic field. (* P,0.05).
doi:10.1371/journal.pone.0015590.g005
OE-MSCs as a Model for FD
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15590Figure 6. Expression and alternative splicing of IKBKAP mRNA at the extremities of the coding sequence. Two additional splicing events
are described within IKBKAP gene. The first one represents the alternative use of a 39ss for exon 2 and the second one concerns exon 36 skipping, as
OE-MSCs as a Model for FD
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significantly enhances the ratio 6 h after its addition to the culture
(Figure 7E). Interestingly, time-response of kinetin was maximal at
24 h during treatment, but its effect on splicing lasted more than
6 h after the drug was washed out and WT transcript levels
remained high compared to non-treated cells, at least 24 h after
the wash out. Consistent results were observed for IKAP/hELP1
protein expression by western blot analysis, although a strong
decrease of protein amount appeared after 24 h of wash out
(Figure 7F).
Finally,wewantedtoinvestigate kinetinactivityalongthe IKBKAP
transcript. Therefore, we compared the level of expression of
IKBKAP transcripts by RT-qPCR to focus on different transcript
regions for both control and FD hOE-MSCs, with or without the
presence of 80 mM kinetin for 24h. We first observed that the total
amount of IKBKAP transcript detected was almost identical when
probes at the extremities or in the middle of the transcript were used
(Figure 7G). In addition, kinetin has no significant effects on IKBKAP
transcript levels in control cells, which likely excludes a potential
action of kinetin on IKBKAP transcription. Moreover, kinetin, by
improving IKBKAP exon 20 recognition, restores IKBKAP transcript
levels in FD hOE-MSCs similar to those observed in control cells
(Figure 7G). Kinetin did not modify the ratio of alternative splicing
around exon 2 and exon 36, suggesting its specific mechanism of
action on exon 20 inclusion (data not shown).
Altogether, these results revealed that kinetin exerts a rapid and
possibly long lasting effect on IKBKAP mRNA splicing, which most
likely occurs by increasing IKBKAP mRNA stability rather than
acting on transcription.
FD sphere cells display a strongly reduced IKBKAP exon
20 skipping
One property of multipotent cell consists in their capacity to
organize into spheres when cultured in appropriate medium. Since
FD hOE-MSCs express a significant amount of MU IKBKAP
transcript we asked whether induction of sphere formation could
modify the WT:MU IKBKAP transcripts ratio.
Although hOE-MSCs proliferate as adherent cells, when
cultured in DMEM-F12 supplemented with serum (Figure 8A),
they progressively organize into spherical aggregates when
cultured in serum-free medium in the presence of EGF and bFGF
(Figure 8B and C). Both control and FD hOE-MSCs were able to
form spheres in approximately one week, and immunostaining
with anti-b-III tubulin (Figure 8D) and anti-nestin (Figure 8E)
antibodies revealed a similar staining of both markers for control
and FD cells (Figure 8F). Total RNAs, isolated from either FD
spheres, FD cells cultured in serum during the same period, or
dissociated cells from spheres that were reintroduced in serum
medium for 24 h, were subjected to RT-qPCR. We observed a
significant increase of IKBKAP exon 20 inclusion in spheres, when
compared to hOE-MSCs in serum conditions, as well as a semi-
disappearance of IKBKAP exon 20 skipping (Figure 8G). Dissoci-
ated spheres re-exposed to serum rapidly expressed initial levels of
WT and MU transcripts (Figure 8G). We quantified WT and MU
transcript level of expression in these 3 different conditions and
confirmed that spheres formation from FD hOE-MSC induces
IKBKAP mRNA splicing correction, using RT-qPCR (Figure 8H).
We also looked for exon 2 and exon 36 alternative splicing events
but did not detect significant alterations of splicing ratio resulting
from sphere formation and dissociation (data not shown).
Commitment of FD OE-MSCs into neuronal and glial
lineages leads to a more severe IKBKAP exon 20 skipping
FD hOE-MSCs were treated for 7 days to induce neuronal
differentiation with a protocol previously used in hOE-MSC [41],
which consists of additing retinoic acid, forskolin, and Sonic
hedgehog in the medium (called rafnshh medium). Cells were first
cultured in serum-free medium supplemented with N2 and B27
until they became adherent before being cultured in rafnshh
(Figure 9B). The new culture medium induced a slight morphology
change, as compared to the serum condition (Figure 9A). When
hOE-MSCs were first cultured in rafnshh, they began to form long
fine processes and neural-like cells (Figure 9C). After 7 days of
treatment, a majority of cells adopted neuron-like morphologies
(Figure 9D) and established a wide range of connections
(Figure 9E, F and M). Using end-point PCR on 3 different FD
cell cultures, we observed that IKBKAP mRNA splicing in rafnshh-
treated cells was more prone to exon 20 skipping as compared to
untreated cells (Figure 9G). This change can be quantified by RT-
qPCR (Figure 9H). In contrast, we did not detect significant
variations in exon 2 and exon 36 alternative splicing during
neuronal differentiation (data not shown).
When assessing immunostaining on treated cells, we observed
that rafnshh treatment increased the proportion of both GFAP
(Figure 9I and J) and MAP2-expressing cells (Figure 9K and L).
Double-labeling with b-III tubulin and nestin revealed a stronger
expression of b-III tubulin compared to nestin during the
differentiation process (Figure 9N–P). Collectively, these results
indicate that rafnshh treatment influences the neural and glial
lineage commitment. As a consequence, the splicing machinery in
neuron or astrocyte-differentiated cells is impaired for IKBKAP
exon 20 recognition.
Discussion
Deciphering the molecular basis of the tissue-specific pattern of
IKBKAP mRNA splicing in FD nervous tissues is crucial for the
comprehension of disease physiopathology in this genetic neuro-
logical disorder affecting neuronal development and survival. In
this study, we aimed to recapitulate different aspects of IKBKAP
gene expression using FD hOE-MSCs cultured with different
conditions. While other human cellular models, such as fibroblasts
or iPS cells, have been investigated to understand FD, we believe
that hOE-MSCs hold a great promise to model the FD disease
pathology. hOE-MSCs are easily obtained by a simple biopsy and
can be maintained for an extended period of time and can be
rapidly expanded in basic culture conditions without genetic
manipulation. In addition, due to the origins of hOE-MSCs from a
peripheral tissue, these cells are able to express neuroglial markers
in vitro (Figure 1, [42–47]). Thus, they constitute an efficient and
simple method to derive neuronal cells in the original context of
the genetic mutation studied.
represented by a schematic (A). B, semi-quantitative RT-PCR illustrates relative amounts of both events on 2 control and 2 FD hOE-MSCs. C, RT-qPCR
analysis performed at 2 different regions (exon 2 and exon 36), using 4 control and 4 FD samples, at the same cell passage (P7). Histograms represent
the mean value of 4 samples, normalized with ABL1 gene. (*** P,0,001 using two-tailed Student’s test). IKAP/hELP1 truncated regions for all splicing
events are represented by a schematic (D). Grey portions represent the conserved amino acids while black portions represent new amino acids
resulting from a frame shift. Putative functional domains of the protein are indicated as well as the immunogenic region for the monoclonal antibody
used in western blot and immunocytochemistry experiments.
doi:10.1371/journal.pone.0015590.g006
OE-MSCs as a Model for FD
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e15590In contrast to control cells, which constitutively include IKBKAP
exon 20, we confirmed the alternative splicing of that exon in FD
cells (Figure 2A). Similar to neural precursors obtained from iPS
cells [22], FD hOE-MSCs predominantly express the MU IKBKAP
transcript isoform (Figure 2A and B). Moreover, we demonstrated
that FD cells exhibit notably lower IKBKAP transcript levels
(WT+MU), when compared to controls (Figures 2B, 6C and 7G).
Such a difference is most likely explained by an extensive
degradation of MU transcripts through the NMD pathway
(Figure 2D), as was previously suggested [35]. However, NMD
efficiency varies between cell types and individuals [48–50] and it
is unclear how prevalent this mechanism of mRNA degradation is
in the nervous system of FD individuals. In order to get a better
insight into the actual contribution of NMD on the decay of
IKBKAP MU transcripts, it will be necessary to specifically block
the NMD machinery.
Figure 7. Action of kinetin on IKBKAP mRNA splicing in FD hOE-MSCs cells. A–C, hOE-MSCs were treated with increasing concentration of
kinetin for 72 h. (i) Total RNAs were reverse transcribed and subjected to both semi-quantitative PCR (A) and absolute qPCR (B) of WT and MU IKBKAP
transcripts, (ii) total lysates were analyzed by western blot using a monoclonal mouse anti-IKAP/hELP1 antibody (C). D–F, kinetics of hOE-MSCs
incubated for 24 h with 80 mM kinetin which was then removed for the next 24 h. Total RNAs were reverse-transcribed and subjected to IKBKAP-
specific semi-quantitative PCR (D) and absolute RT-qPCR (E). Total lysates were analyzed by western blot (F). The level of WT and MU transcripts was
normalized using ABL1 as a reference gene (B and E). G, Two controls (CTRL) and two FD hOE-MSCs treated or not with 80 mM kinetin for 24h were
analyzed by absolute RT-qPCR to determine the amount of IKBKAP exon 2 inclusion, exon 20 inclusion, exon 20 skipping, and exon 36 exclusion after
normalization with ABL1.( *P,0.05; *** P,0,001 using two-tailed Student’s test).
doi:10.1371/journal.pone.0015590.g007
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various cellular localizations. This has been the matter of a
controversy because several studies have failed to detect IKAP/
hELP1 in the nucleus or found it almost exclusively in the
cytoplasm [11,21,34,51], which is difficult to reconcile with its
suggested role in transcription elongation. As observed in most
published studies, we observed that the immunolocalization of
IKAP/hELP1 was mainly cytoplasmic within the perinuclear area.
However, we also detected significant nuclear staining in
agreement with other reported studies [9,52]. Altogether, our
findings of IKAP/hELP1 distribution in hOE-MSCs support
multiple roles for the protein within different subcellular
compartments.
In order to establish a direct link between low levels of IKBKAP
WT transcripts and decreased neuronal populations in FD patients,
several groups have investigated transcriptome variations resulting
from a reduced level of IKBKAP transcripts using microarray
technology [10,22,34,40,53]. However, poor correlations were
observed between these studies. Several reasons can explain these
discrepancies. First, various cell types, used at different stages of
development and differentiation, have been studied (brain tissue,
fibroblasts, HeLa cells, HCT116 cells, iPS cells). The cells tested in
the current study are likely at a stage between the iPS and iPS cell-
derived neuralcrest precursors developedby the Studer group [22].
It is thus not surprising that most of our microarray results overlap
with that of the iPS cell study. Second, a potential source of
variability among transcriptome analyses derives from the technical
manipulations employed to downregulate IKBKAP (presence of the
FD mutation in its original context compared to WT IKBKAP
knockdown using different interfering RNAs), resulting in differ-
ential residual IKBKAP/IKAP expression. Third, in the context of a
rare disease, a small sample size may cast doubt upon the validity of
drawn conclusions. To decrease statistical bias, we decided to
increase the number of samples of our 5 control and 4 FD patients
by collecting data from 4 different passages (P1, P2, P5 and P9) of
each primary cell line. We hypothesized was that such a method
would allow us to i) increase the statistical power of our analysis,
and ii) explore the effects of culture conditions on gene expression.
We anticipated that a strong gene dysregulation observed in
microarray would be more significant if this expression is stably
maintained at any cell passage. Most of the differentially expressed
genes were found to have a modest (,2) fold-change (Table 1).
Interestingly, like previous studies, we observed that a majority of
genes were down-regulated in FD hOE-MSCs (Table 1, negative
values), and only 4 genes were up-regulated (Table 1 and Table S1,
positive values). This observation is in agreement with other studies
[10,22,40] and may reflect a defect in transcription due to
decreased Elongator activity, as previously proposed [10]. Impor-
tantly, 10 genes in our list (20%) appeared to be correlated with one
or two previous investigations (Table 1 and Table S1, last column).
In one of the past studies, IKBKAP expression level can be
downregulated by RNAi in control cells [10], where there is no
production of MU transcripts. Thus, different studies share
dysregulated genes in different contexts of either constitutive or
alternative splicing of IKBKAP mRNA. This suggests that IKBKAP
alternative splicing may not be the only pathological alteration
in FD.
Similar to what was previously reported, our study revealed the
downregulation of gelsolin (GSN), a protein involved in cell
motility, that causes defects in cytoskeleton reorganization and cell
migration in FD [10,11,22,34]. The most dysregulated gene
observed in our study was PMEPA1 (24.92 fold change), encoding
the TMEPAI protein which has recently been reported to be a
direct target of the TGF-b signaling pathway and is involved in
cell growth, cell differentiation, and apoptosis [54]. Due to its
important cellular function and repeated reports of its dysregula-
tion in FD cells, it would be very interesting to test TMEPAI in
further studies. In agreement with previous studies correlating a
decreased expression of IKAP/hELP1 with defects in cell
migration [10,11,22,34], the Boyden’s chamber assay show that
FD hOE-MSCs have decreased migration potential, compared to
control cells (Figure 5).
Figure 8. WT:MU ratio is increased in hOE-MSC-derived spheres. FD hOE-MSCs cultured in serum (A) gave rise to spheres when plated in
medium supplemented with ITS and growth factors (B and C). Immunostaining showed b-III tubulin and nestin positive spheres (D, E, F). RNA was
isolated from 2 different FD hOE-MSCs cultured first in serum, then induced to form spheres, and finally dissociated and replated in serum conditions
for 24h (G). RT-qPCR was performed on the same samples and histograms represent the mean value of the two FD samples after normalization with
ABL1 gene (H). Scale bars represent 100 mm. (* P,0,05, ** P,0,01 using two-tailed Student’s test).
doi:10.1371/journal.pone.0015590.g008
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our microarray analysis. This result is all the more intriguing since
this gene is expressed at much lower levels in FD hOE-MSCs, as
shown by RT-qPCR in the exon 20 region (Figure 2B). However,
previous analyses using microarrays also failed to detect IKBKAP as
a down-regulated gene in FD cells [22,40]. To address the
question of a possible PCR artifact or lowered microarray
sensitivity and because the FD mutation is located in the middle
region of the IKBKAP gene, we performed quantitative PCR at
both ends of the IKBKAP gene.
Unexpectedly, we identified 2 new events of alternative splicing
at both extremities of IKBKAP coding sequence (Figure 6A).
However, these results are in agreement with EST sequences
found in alternative splicing database such as ASD [55]. We
Figure 9. WT:MU ratio is decreased in differentiated hOE-MSCs. A, Phase contrast microscopy of FD hOE-MSCs cultured for 48 h in either
serum (A), or N2B27 conditions (B), or with the rafnshh cocktail including retinoic acid, forskolin and Sonic hedgehog (C), or rafnshh for 7 days (D).
Details of connections established between cells and extensive cellular arborization after 7 days in rafnshh condition are shown in E and F. G, agarose
gel electrophoresis of semi-quantitative RT-PCR products showing IKBKAP WT and MU transcripts of 3 differents FD patients before and after rafnshh
treatment. H, histograms represent the mean level of IKBKAP transcripts expression normalized with ABL1 gene expression for 3 FD patients, after RT-
qPCR analysis. (* P,0,05, using two-tailed Student’s test). FD hOE-MSCs treated for 7 days in rafnshh were fixed and stained for GFAP (I, one cell with
ramified neuritic process is magnified in J), MAP2 expression (K and L). M–P, double labelling of rafnshh-treated cells with anti-b III tubulin and anti-
nestin antibodies. Scale bars represent either 50 mm (A–D, I, K, M–P) or 25 mm (E–F, J, L).
doi:10.1371/journal.pone.0015590.g009
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start codon) leads to a shorter exon 2 which can potentially induce
the use of an alternative ATG start codon (in exon 4), resulting in
the synthesis of an N-terminal truncated IKAP/hELP1 protein. In
addition, we detected the presence of intronic sequences at the end
of IKBKAP gene leading to a supplementary exon in the mRNA,
named ‘‘exon 36’’. This exon inclusion also induced a frameshift
and resulted in a premature stop codon whose relative location
likely led to NMD of this new isoform, as observed by stabilization
of the transcript after cycloheximide treatment (Figure S2).
IKAP/hELP1 plays the role of a scaffold protein in Elongator
complex assembly and the C-terminus half of IKAP/hELP1 is
responsible for this function [34]. It has also been shown that
IKAP/hELP1 contains five WD-like repeats domains in the N-
terminal part that may play a role for protein-protein interactions
[56]. When comparing the different protein isoforms resulting
from the 3 alternative splicing events we described (Figure 6D),
only the isoform resulting from exon 20 skipping seems to lack a
functional domain and may play a pathological role during FD
progression. However, the protein domains of IKAP/hELP1
important for Elongator integrity have not been precisely mapped
and other roles for IKAP/hELP1 have been proposed outside of
the Elongator complex. Thus, it is not clear whether the new
IKBKAP isoforms we described, may have functional roles. Future
investigations with specific reagents (antibodies) will be required to
address this issue.
Nevertheless, we consistently detected a lower expression of
IKBKAP gene (including the full length exon 2 transcript and the
transcripts skipping exon 36) in FD hOE-MSCs (Figure 6C), as
determined when investigating the exon 20 region. Thus, the
relatively stable expression of IKBKAP observed in microarray
analysis may be due to a weak expression that is masked within the
noise signals. Furthermore, during the analysis of our microarray
data and those of previous studies [10,22,40] we noticed that a
high fraction of genes were expressed at background levels. This
points to the limitation of using microarray technology to establish
the whole genome expression pattern. We expect that new
technologies such as RNA deep sequencing will rival PCR
sensitivity and specificy in the near future.
The model of hOE-MSCs from FD patients has also been very
useful to test compounds, such as kinetin, that can correct the
defective splicing process. As reported in the other cell types tested,
we confirmed that kinetin corrects splicing in a dose-dependent
manner in FD hOE-MSCs (Figure 7A–C). This suggests that
kinetin activity is not cell-type specific. Although the mechanism
by which kinetin modulate splicing remains poorly understood
[36,57], it is unlikely that kinetin acts directly on the general
transcription machinery as the level of IKBKAP transcripts was not
significantly modulated by kinetin in control hOE-MSCs
(Figure 7G). This effect of kinetin has also been previously
observed in control iPS cells [22]. Time-course experiments of
kinetin treatment revealed that the drug acts quite rapidly on
correcting IKBKAP mRNA splicing and enhancing IKAP/hELP1
synthesis, but its effects last only a short time after removal
(Figure 7E and F). This information provides new perspectives in
the strategy of kinetin delivery to FD patients. First, kinetin as an
FD treatment would potentially decrease deleterious consequences
of the mutation at the protein level. In addition, drug efficacy may
be achieved if adequate levels of kinetin is maintained over a long
period of time. However, as observed for FD iPS cells [22], kinetin
did not improve cell migration in FD hOE-MSCs (Figure 5),
suggesting incomplete phenotype complementation.
Using the hOE-MSCs model, we were also able to modulate the
expression of IKBKAP WT and MU transcripts, by exposing the
cells to different culture conditions to simulate variations in
alternative splicing occurring during development and differenti-
ation. hOE-MSCs form free floating spheres in approximately 7
days, when cultured with EGF and bFGF in serum-free medium.
It is known that in sphere conditions, cells can form a niche
prevent differentiation and ensure self-renewal. The cell popula-
tions contained in hOE-MSC-derived spheres are not well-known.
Some reports indicate that they include an heterogeneous mixture
of stem cells and neuroglial progenitors [29,43,44,47,58].
However, immunostainings of nestin and b-III tubulin show no
significant differences. Interestingly, PCR analysis demonstrated
that spheres express higher levels of WT IKBKAP transcript
compared to hOE-MSCs in serum and express very flow levels of
MU transcript. However, when the cells were transferred back to
culture conditions with serum, the enhanced IKBKAP exon 20
inclusion was not maintained (Figure 8G and H). FD hOE-MSCs
that were cultured in serum-free conditions without forming
spheres did not exhibit significant changes in IKBKAP isoforms,
suggesting that there is subpopulation of cells within the spheres
that can promote IKBKAP exon 20 inclusion. These results indicate
that when FD cells are turned back into a more ‘‘primitive’’
developmental stage, IKBKAP aberrant splicing is corrected, as was
described during the fibroblast to iPS cell reprogramming process
[22]. Accordingly, commitment into a more differentiated
neuronal state would alter IKBKAP exon 20 inclusion. Therefore,
we differentiated FD hOE-MSCs, using a previously established
protocol which included retinoic acid (RA), forskolin (FN), and
Sonic hedgehog (Shh) in the culture medium [44]. In these
conditions, we observed that differentiated cells express the highest
levels of MU IKBKAP transcript (Figure 9G and H). This result
correlates with the specific low WT:MU IKBKAP isoform ratio in
nervous tissues [8], and suggests that stem cells engaged in a
neuronal lineage with appropriate culture conditions can rapidly
switch their IKBKAP WT:MU transcript ratio.
Previous studies have shown that i) IKBKAP exon 20 is poorly
defined in a ‘‘healthy’’ context, due to the presence of a weak 39ss
and exonic splicing silencers, and ii) the FD mutation exacerbates
the environment leading to alternative exon 20 inclusion in FD
tissues [59,60]. We propose that some transcription/splicing
factors involved in IKBKAP exon 20 recognition are also
downregulated in a tissue-specific manner. This would explain
why the pattern of IKBKAP alternative mRNA splicing is more
aberrant in the nervous system. Interestingly, Lee and colleagues
determined that the neuron-specific splicing factor NOVA1 [61]
was underexpressed in FD versus control iPS cell-derived neural
crest precursors [22]. The new model described in this study will
allow us further test whether candidate splicing factors may be
involved in the tissue-specific regulation of IKBKAP mRNA
alternative splicing.
Materials and Methods
Ethics Statement
All control and FD participants gave informed and written
consents (provided by the parents for the children) and biopsies
were obtained under a protocol, which was approved by the local
ethical committees in New York (Institutional Review Board of the
New York University School of Medicine) and Marseille (Comite ´
Consultatif de Protection des Personnes dans la Recherche
Biome ´dicale Marseille 2).
Purification of hOE-MSCs
Human nasal mucosae were obtained from biopsies of 4 FD
patients (3 females and 1 male aged 12–16 years) at the
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four FD patients were homozygous for the splicing mutation.
Biopsies form 5 healthy controls (3 females and 2 males, aged 18–
39 years) were collected by the ENT Department in Marseille
(Hopital Nord, France). Biopsies were harvested as previously
described [30,46] to obtain a cell culture of hOE-MSCs. The cells
were continuously cultured in DMEM/HAM’S F12 (Gibco)
supplemented with 10% fetal bovine serum (FBS) and 50 mg/ml
gentamicin (Gibco) and trypsinized once a week with 0.05%
trypsin-EDTA (Gibco) at 60–80% confluence. Cycloheximide
(Sigma), diluted in DMSO, was used at 50 mg/ml. Kinetin solution
(Sigma, 1 mg/ml) was diluted in DMEM/HAM’S F12 at
concentration ranging from 25 to 200 mM for various incubation
times, as specified in the text.
Generation of spheres and cell differentiation
Cells were plated at 15,000 cells/cm
2 into 6-well plates
preteated with poly-L-lysine (5 mg/cm
2, Sigma) in a serum-free
medium of DMEM supplemented with insulin-transferrin-seleni-
um (ITS, 1g/l insulin, 0.55 g/l transferrin, 0.67 mg/l sodium
selenite; Gibco), epidermal growth factor (EGF, 50 ng/ml, R&D
system) and basic fibroblast growth factor-2 (bFGF, 50 ng/ml,
R&D system). Half of the medium was changed every 2 days.
Multipotent spheres were obtained after 1 week and harvested by
aspiration of the culture medium and centrifugation (5 min, 300g).
They were then incubated in Accumax solution (Sigma), for
10 min at 37uC. To release more cells, the sample was gently
triturated by repeated pipetting. When disaggregation was
complete, cells were centrifugated (5 min, 300g) to remove cell
debris. For cell differentiation, hOE-MSCs were plated on glass
coverslips at the density of 10,000 cells/cm
2 (in six-well plates for
RNA extraction, and 24-well plates for immunostaining), in
serum-free medium supplemented with 1% ITS, 1% B27 and
0.5% N2, until adhesion. Cells were then treated with 1% ITS,
1 mM all-trans retinoic acid (Sigma), 5 mM Forskolin (R&D
Systems), 15 nM Sonic hedgehog (R&D Systems), 1% B27 and
0.5% N2 for 7 days without changing the medium.
Immunocytochemistry
Cells grown on glass coverslips were fixed with 4% parafor-
maldehyde for 20 min at room temperature and rinsed three times
with phosphate-buffered saline (PBS). Cells were preincubated for
60 min at room temperature with blocking buffer (3% BSA in PBS
with 0.1% Triton X-100 and 10% normal goat serum), followed
by incubation with the primary antibodies diluted in the blocking
buffer. Coverslips were processed for immunofluorescence staining
using the following primary antibodies: rabbit anti-nestin (1:500,
Abcys), mouse anti bIII-tubulin (1:500, Sigma, clone SDL.3D10),
rabbit anti-GFAP (1:500, Dako), rabbit anti-MAP2 (1:500,
Abcam), mouse anti-IKAP/hELP1 (1:100, BD Biosciences, clone
33). Each primary antibody was applied for 2 h at room
temperature. For IKAP/hELP1 staining, primary antibody was
incubated 3 h at room temperature followed by an overnight
incubation at 4uC. We used appropriate secondary antibodies:
goat anti-rabbit IgG conjugated with AlexaFluor 594 (1:500,
Invitrogen), goat anti-mouse IgG conjugated with AlexaFluor 488
(1:500, Invitrogen) for 1 h at room temperature. Hoechst nuclear
dye was used to label nuclei (1:2,000, Molecular Probes, #33258).
Coverslips were finally mounted with anti-fading medium
(ProLongH, invitrogen). Cells were observed under a Nikon
Eclipse E800 upright microscope equipped with epifluorescence
and TRITC, FITC and DAPI filters, and images were analyzed
using an Orca-ER CCD camera (Hamamatsu Photonics) and the
LUCIA image analysis software (Laboratory Imaging). Confocal
image acquisition was performed on a Leica TCS SP2 confocal
microscope (Leica Microsystems) using the 488-nm band of an
argon laser for excitation of Alexa 488 and the 680-nm band of an
argon laser for excitation of Alexa 680. High magnification images
were acquired using a 636 HCX PL APO (with 4 digital zoom
factor) oil immersion objective (numerical aperture 1.32) by
sequential scanning to minimize the crosstalk of fluorophores.
Pinhole size was set to ‘Airy one’’ to achieve the best possible
resolution (theoretical lateral and axial limits: 165 and 330 nm,
respectively). Voxel size was set to 58 nm in x and y and to
162 nm in z.
Western blot analysis
Cells were harvested by trypsination and centrifugation (5 min,
300g). The pellet, containing approximately 10
6 cells, was
resuspended in 0.5 ml 26 Laemmli buffer (0.5 M Tris pH 6.8,
4.4 ml Glycerol, 20% SDS, 1% Bromophenol Blue, 0.5 ml b-
mercaptoethanol). 30 ml of cell lysates were separated on 6.5%
SDS-polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane (Amersham Biosciences). After blocking
with 5% nonfat milk in PBS, 0.1%, tween 20 (PBST) buffer, blots
were probed for 1h at room temperature with a mouse
monoclonal anti-IKAP antibody (1:5,000, BD Biosciences, clone
33) in PBST, followed by incubation with horseraddish peroxi-
dase-conjugated goat anti-mouse IgG (1:5,000, Jackson Immunor-
esearch) for 45 min at room temperature. As a control, the
membrane was also probed for b-actin (1:3,000, Sigma, clone
SDL.3010). Proteins were visualized by chemiluminescent detec-
tion using the ECL detection kit (Enhanced Chemiluminescence,
Amersham) and films were digitized and analyzed using the Bio
1D software.
RNA Isolation and semi-quantitative reverse
transcription-polymerase chain reaction analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen)
with DNAse treatment on the column according to manufacturer’s
recommendation. Total RNA was subjected to reverse transcrip-
tion (RT) using the High-Capacity cDNA Archive Kit (Applied
Biosystems). End-point polymerase chain reaction (PCR) analysis
was performed using the Go-Taq polymerase system (Promega)
and IKBKAP-specific primers listed in Table 2. PCR products were
separated on a 1.7% agarose gel by electrophoresis in 16 TBE
buffer (Tris 0.89 M, boric acid 0.89 M and EDTA 0,02 M). DNA
was visualized under UV light after ethidium bromide incorpo-
ration and documented using BioVision Camera.
Plasmid calibrators
A fragment of WT IKBKAP cDNA, containing exon 19-exon
20-exon 21 and the 16 first nt of intron 21, was cloned into
pcDNA 3.1 TOPO vector (Invitrogen) and named IKBKAP cDNA
cal. Similarly, a piece of MU IKBKAP cDNA, containing exon 19-
exon 21 and the 19 first nt of exon 22, was cloned into a pcDNA
3.1 TOPO vector and named IKBKAP skipEx20cal. A piece of
WT IKBKAP cDNA, containing the last 103 nt of exon 35-exon37-
exon38 first 90 nt, was cloned into KpnI-XbaI cloning sites of
pcDNA 3.1 TOPO vector and named IKBKAP skipEx36cal. A
piece of WT IKBKAP cDNA, containing the last 30 nt of exon1-
exon2-exon3 first 110 nt, was cloned into KpnI-XbaI cloning sites
of pcDNA 3.1 TOPO vector and named IKBKAP fullEx2cal. For
ABL1, the last 37 nt of exon 2 and first 102 nt of exon 3 were
amplified from ABL1 cDNA, cloned into KpnI-XbaI cloning sites
of pcDNA 3.1 TOPO vector and named ABL1 cal. All plasmid
calibrators were linearized with XbaI and serially diluted in a
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of E. coli 16S and 23S rRNA (Roche).
Real-time PCR assay
The PCR reactions were performed in triplicate in a final volume
of 25 ml, including 300 nM primers, 200 nM TaqManH probe,
12.5 ml of TaqManH universal PCR master mix (Applied
Biosystems) and 5 ml of either cDNA or plasmid calibrator in a
AB Prism 7900 HT thermocycler with 50 cycles and the protocol
recommended by the manufacturer. For relative quantification and
microarray results validation, we selected primer sets and probes,
matching sequences present in the IMAGE human cDNA clones
of the nylon microarrays with those displayed on the web
portal of Applied Biosystems. The assay IDs were the following:
Hs00375306_m1 (PMEPA1) and Hs00293488_m1 (S100A16) for
the dysregulated genes in FD, and Hs01003267_m1 (HPRT1)a n d
Hs00293488_m1 (RPLP0) for reference genes used to normalize the
data. We alsoused previously validated primers and probe for ABL1
as a third reference gene [62]. Results were calculated using the
2(2DDCT) method [63]. For absolute quantification, IKBKAP
primers and hydrolysis probes (FAM TAMRA) were designed using
the Primer 3 software and are listed in Table 2. Serial dilutions of
plasmid calibrators (10
6,1 0
5,1 0
4,1 0
3,1 0
2 copies in 5 ml) were
prepared and used to construct the standard curves. The number of
IKBKAPandABL1 transcripts was extrapolatedautomatically bythe
Sequence Detection System v2.2.2 software (Applied Biosystems).
Microarray analysis and normalization
RNA integrity was assessed using an Agilent 2100 Bioanalyser
(Palo Alto, CA). Samples with an RNA integrity number (RIN),9
were excluded from the analysis (the samples concerned were
C2P5, C3P5, and FD2P5). Gene expression analyses were carried
out with cDNA Nylon microarrays containing 8,780 spotted
cDNA clones and radioactive detection as previously described
[64], with 5 mg of RNA reverse transcribed (oligo-dT priming) in
presence of [a-
33P]dCTP (Amersham Pharmacia Biotech). Details
about microarray construction, clones list, probes preparations,
hybridizations and washes have been previously described [65].
After image acquisition, signal intensities were quantified using
BZScan software (http://tagc.univ-mrs.fr/bioinformatics/bzscan,
[66]). A specific R library that uses the ‘S4’ system of formal classes
and methods was used to process and normalize nylon microarray
data [67]. Quantile normalization was applied to vector probe
data (V) and complex probe data (C), to correct for global intensity
and dispersion. Correction by the vector signal was made for each
spot signal by calculating a C:V ratio before log transformation
(base 2). No background correction or overshining correction was
used. All data are MIAME compliant and have been loaded into
ArrayExpress database (http://www.ebi.ac.uk/microarray-as/ae/)
under accession number E-MTAB-281.
Statistical and gene ontology analysis
Significant Analysis of Microarray (SAM version 1.13; Stand-
ford University) was applied to determine significant differential
gene expression using the Multiexperiment viewer (MEV)
program. The data were analyzed using a two-class unpaired
response type, which compared control samples versus FD
samples. SAM calculated a significant score for each gene based
on the gene expression change relative to the standard deviation of
repeated values for that gene. We used 100 permutations and a
Table 2. Sequence of primers used for end-point and TaqMan real-time PCR.
Primer Probe Sequence T (6C)
a Amplicon size (bp) Splicing events
End-point PCR
hIKBKAP ex17-18F TCATCAATGACATTGAGGTTG 55 446 (WT) ex20 incl/skip
hIKBKAP ex22R ATGATTCACAGAATCTATCTG 372 (MU)
hIKBKAP ex1F CCGGACGCACCTCTGTTTG 60 485 alt 39ss for ex2
hIKBKAP ex4-5R TCAGGGTCTGTTGACCTGTG 340 (alt 39ss ex2)
hIKBKAP ex33-34F TCCAGGATATCAGCGAGATC 59 449 ex36 incl/skip
hIKBKAP ex37R GCTGATAAGATGCCATGATAC 346 (- ex36)
hIKBKAP ex35-36R TTGGGACCTAGAACACCTGT 59 414 ex36 incl
Real-time PCR
hELP1 ex19F GGTTCACGGATTGTCACTGTT 60 133 ex20 incl
hELP1 ex20-21R ACATAAGTTTGTCCAACCACTTCC
P-WTELP1 ex20R AAACCAGGGCTCGATGATGAACA
hELP1 ex19-21F GGACACAAAGCTTGTATTACAGACTTA 60 121 ex20 skip
hELP1 ex21-22R CCACATTTCCAAGAAACACCT
P-MUELP1 ex21F AGAGGCATTTGAATGCATGAGAAAGC
hELP1 ex2F CCAGGGAATCCTCAGTGCT 60 104 full length ex2 incl
hELP1 ex2-3R TTCACTTCTCTTGAGACAGGGTCTAC
P-WTELP1 ex2F TCCGACTGAACAGGGGACGGT
hELP1 ex35-37F CAGCTACCCCGGTTCTAGGT 60 128 ex36 skip
hELP1 ex38R GGTTCTTCTGTTGATCTTTGGTG
P-WTELP1 ex37-38R AAGCTCAGCATCAAGAACAGGAACC
aAnnealing temperature.
doi:10.1371/journal.pone.0015590.t002
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the heat map generation were called as significant with a p-
value,0.006. For gene ontology analysis, we generated a set of
human protein associated with the gene appearing as significant
with the SAM test, by using the BioKnowledgeH Library (BKL)
Retriever
TM search tool (http://www.biobase-international.com/).
This set of proteins was analyzed for overrepresentation of Gene
Ontology (GO) Biological Process (BP) terms.
Boyden chamber-based cell migration assay
hOE-MSCs were detached by trypsin/EDTA, counted and
seeded into the upper chamber of transwell polyethylene
terephtalate filter membranes with 8 mM diameter pores (BD
Biosciences), at a density of 3610
4 cells/well, in a final volume of
200 ml serum or serum free culture medium, with or without
100 mM kinetin. Cells were allowed to migrate through the
membrane filter for 24h at 37uC, 5% CO2. Cells migrating
thought the membrane pore and invading the underside surface of
the membrane were fixed with 4% paraformaldehyde. Non-
migratory cells on the upper membrane surface were removed
with a cotton swab, and nuclei were stained with 0.5 mg/mL DNA
intercalant Hoechst #33258. For quantitative assessment, the
number of stained migrating cells was counted with imageJ
software on 10 random fields per membrane filter at 620
magnification.
Supporting Information
Figure S1 50 genes are differentially expressed between
control and FD hOE-MSCs. Heatmap representation of
overexpressed (red) and underexpressed (green) genes in 5 controls
and 4 FD OE-MSCs at passage 1,2,5, and 9. Normalized signal
intensities were treated with the SAM software to highlight the
most differentially expressed genes, with a FDR set at 3%.
(TIF)
Figure S2 IKBKAP exon 36 inclusion increases after
cycloheximide treatment. NMD pathway was blocked by the
translation inhibitor cycloheximide and results in an elevated
expression of exon 36-including transcripts in 2 FD OE-MSC
cultures (FD3 and FD4) as determined by absolute RT-qPCR.
(* P,0.05).
(TIF)
Table S1 Dysregulated genes involved in other
processes.
(DOC)
Acknowledgments
We wish to thank the patients and their families for their contribution to
this study. Furthermore, we thank Dr. Joseph Bernstein, Dr. Arnaud
Deveze and Dr. Jacques Magnan for their support in collecting biopsies.
We also thank Denis Puthier for his expertise in bioinformatics analysis, as
well as Adlane Ould-Yahoui for technical help, Andre ´ Verdel and Jeanne
Hsu for critical reading of the manuscript.
Author Contributions
Conceived and designed the experiments: NB FF FBA ECI. Performed the
experiments: NB BL AB OS CFT ECI. Analyzed the data: NB ECI.
Contributed reagents/materials/analysis tools: JG MK CN FF FBA.
Wrote the paper: NB ECI.
References
1. Axelrod FB, Iyer K, Fish I, Pearson J, Sein ME, et al. (1981) Progressive sensory
loss in familial dysautonomia. Pediatrics 67: 517–22.
2. Pearson J, Pytel BA, Grover-Johnson N, Axelrod F, Dancis J (1978) Quantitative
studies of dorsal root ganglia and neuropathologic observations on spinal cords
in familial dysautonomia. J Neurol Sci 35: 77–92.
3. Pearson J, Pytel BA (1978) Quantitative studies of sympathetic ganglia and spinal
cord intermedio-lateral gray columns in familial dysautonomia. J Neurol Sci 39:
47–59.
4. Axelrod FB (2004) Familial dysautonomia. Muscle Nerve 29: 352–63.
5. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, et al. (2001) Familial
dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 68:
753–8.
6. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, et al. (2001) Tissue-
specific expression of a splicing mutation in the IKBKAP gene causes familial
dysautonomia. Am J Hum Genet 68: 598–605.
7. Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ (2002) Familial
dysautonomia: detection of the IKBKAP IVS20(+6TRC) and R696P mutations
and frequencies among Ashkenazi Jews. Am J Med Genet 110: 253–7.
8. Cuajungco MP, Leyne M, Mull J, Gill SP, Lu W, et al. (2003) Tissue-specific
reduction in splicing efficiency of IKBKAP due to the major mutation associated
with familial dysautonomia. Am J Hum Genet 72: 749–58.
9. Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, et al. (2002)
Purification and characterization of the human elongator complex. J Biol Chem
277: 3047–52.
10. Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, et al. (2006)
Transcription impairment and cell migration defects in elongator-depleted cells:
implication for familial dysautonomia. Mol Cell 22: 521–31.
11. Creppe C, Malinouskaya L, Volvert ML, Gillard M, Close P, et al. (2009)
Elongator controls the migration and differentiation of cortical neurons through
acetylation of alpha-tubulin. Cell 136: 551–64.
12. Solinger JA, Paolinelli R, Kloss H, Scorza FB, Marchesi S, et al. (2010) The
Caenorhabditis elegans Elongator complex regulates neuronal alpha-tubulin
acetylation. PLoS Genet 6: e1000820.
13. Chen C, Tuck S, Bystrom AS (2009) Defects in tRNA modification associated
with neurological and developmental dysfunctions in Caenorhabditis elegans
elongator mutants. PLoS Genet 5: e1000561.
14. Huang B, Johansson MJ, Bystrom AS (2005) An early step in wobble uridine
tRNA modification requires the Elongator complex. RNA 11: 424–36.
15. Esberg A, Huang B, Johansson MJ, Bystrom AS (2006) Elevated levels of two
tRNA species bypass the requirement for elongator complex in transcription and
exocytosis. Mol Cell 24: 139–48.
16. Rahl PB, Chen CZ, Collins RN (2005) Elp1p, the yeast homolog of the FD
disease syndrome protein, negatively regulates exocytosis independently of
transcriptional elongation. Mol Cell 17: 841–53.
17. Okada Y, Yamagata K, Hong K, Wakayama T, Zhang Y (2010) A role for the
elongator complex in zygotic paternal genome demethylation. Nature 463:
554–8.
18. Lipardi C, Paterson BM (2009) Identification of an RNA-dependent RNA
polymerase in Drosophila involved in RNAi and transposon suppression. Proc
Natl Acad Sci U S A 106: 15645–50.
19. Chen YT, Hims MM, Shetty RS, Mull J, Liu L, et al. (2009) Loss of mouse
Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic
lethality that can be rescued by human IKBKAP. Mol Cell Biol 29: 736–44.
20. Hims MM, Shetty RS, Pickel J, Mull J, Leyne M, et al. (2007) A humanized
IKBKAP transgenic mouse models a tissue-specific human splicing defect.
Genomics 90: 389–96.
21. Valensi-Kurtz M, Lefler S, Cohen MA, Aharonowiz M, Cohen-Kupiec R, et al.
(2010) Enriched population of PNS neurons derived from human embryonic
stem cells as a platform for studying peripheral neuropathies. PLoS One 5:
e9290.
22. Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al. (2009)
Modelling pathogenesis and treatment of familial dysautonomia using patient-
specific iPSCs. Nature 461: 402–6.
23. Saha K, Jaenisch R (2009) Technical challenges in using human induced
pluripotent stem cells to model disease. Cell Stem Cell 5: 584–95.
24. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, et al. (2010)
Direct conversion of fibroblasts to functional neurons by defined factors. Nature
463: 1035–41.
25. Kim K, Doi A, Wen B, Ng K, Zhao R, et al. (2010) Epigenetic memory in
induced pluripotent stem cells. Nature 467: 285–90.
26. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, et al. (2010) Cell type of
origin influences the molecular and functional properties of mouse induced
pluripotent stem cells. Nat Biotechnol 28: 848–55.
27. Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, et al. (2010) Persistent
donor cell gene expression among human induced pluripotent stem cells
contributes to differences with human embryonic stem cells. PLoS One 5: e8975.
OE-MSCs as a Model for FD
PLoS ONE | www.plosone.org 16 December 2010 | Volume 5 | Issue 12 | e1559028. Graziadei PP, Graziadei GA (1979) Neurogenesis and neuron regeneration in
the olfactory system of mammals. I. Morphological aspects of differentiation and
structural organization of the olfactory sensory neurons. J Neurocytol 8: 1–18.
29. Murrell W, Feron F, Wetzig A, Cameron N, Splatt K, et al. (2005) Multipotent
stem cells from adult olfactory mucosa. Dev Dyn 233: 496–515.
30. Delorme B, Nivet E, Gaillard J, Haupl T, Ringe J, et al. (2010) The human nose
harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic
and osteogenic properties. Stem Cells Dev 19: 853–66.
31. Feron F, Perry C, Hirning MH, McGrath J, Mackay-Sim A (1999) Altered
adhesion, proliferation and death in neural cultures from adults with
schizophrenia. Schizophr Res 40: 211–8.
32. McCurdy RD, Feron F, Perry C, Chant DC, McLean D, et al. (2006) Cell cycle
alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I
disorder using cell culture and gene expression analyses. Schizophr Res 82:
163–73.
33. Murrell W, Wetzig A, Donnellan M, Feron F, Burne T, et al. (2008) Olfactory
mucosa is a potential source for autologous stem cell therapy for Parkinson’s
disease. Stem Cells 26: 2183–92.
34. Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, et al.
(2008) IKAP localizes to membrane ruffles with filamin A and regulates actin
cytoskeleton organization and cell migration. J Cell Sci 121: 854–64.
35. Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, et al. (2004) Rescue
of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol
Genet 13: 429–36.
36. Hims MM, Ibrahim EC, Leyne M, Mull J, Liu L, et al. (2007) Therapeutic
potential and mechanism of kinetin as a treatment for the human splicing disease
familial dysautonomia. J Mol Med 85: 149–61.
37. Gold-von Simson G, Goldberg JD, Rolnitzky LM, Mull J, Leyne M, et al. (2009)
Kinetin in familial dysautonomia carriers: implications for a new therapeutic
strategy targeting mRNA splicing. Pediatr Res 65: 341–6.
38. Tanabe S, Sato Y, Suzuki T, Suzuki K, Nagao T, et al. (2008) Gene expression
profiling of human mesenchymal stem cells for identification of novel markers in
early- and late-stage cell culture. J Biochem 144: 399–408.
39. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, et al. (2008) Replicative
senescence of mesenchymal stem cells: a continuous and organized process.
PLoS One 3: e2213.
40. Cheishvili D, Maayan C, Smith Y, Ast G, Razin A (2007) IKAP/hELP1
deficiency in the cerebrum of familial dysautonomia patients results in down
regulation of genes involved in oligodendrocyte differentiation and in
myelination. Hum Mol Genet 16: 2097–104.
41. Zhang X, Klueber KM, Guo Z, Cai J, Lu C, et al. (2006) Induction of neuronal
differentiation of adult human olfactory neuroepithelial-derived progenitors.
Brain Res 1073–1074: 109–19.
42. Wolozin B, Sunderland T, Zheng BB, Resau J, Dufy B, et al. (1992) Continuous
culture of neuronal cells from adult human olfactory epithelium. J Mol Neurosci
3: 137–46.
43. Roisen FJ, Klueber KM, Lu CL, Hatcher LM, Dozier A, et al. (2001) Adult
human olfactory stem cells. Brain Res 890: 11–22.
44. Zhang X, Klueber KM, Guo Z, Lu C, Roisen FJ (2004) Adult human olfactory
neural progenitors cultured in defined medium. Exp Neurol 186: 112–23.
45. Winstead W, Marshall CT, Lu CL, Klueber KM, Roisen FJ (2005) Endoscopic
biopsy of human olfactory epithelium as a source of progenitor cells. Am J Rhinol
19: 83–90.
46. Feron F, Perry C, McGrath JJ, Mackay-Sim A (1998) New techniques for biopsy
and culture of human olfactory epithelial neurons. Arch Otolaryngol Head Neck
Surg 124: 861–6.
47. Othman M, Lu C, Klueber K, Winstead W, Roisen F (2005) Clonal analysis of
adult human olfactory neurosphere forming cells. Biotech Histochem 80:
189–200.
48. Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE (2007) The
abundance of RNPS1, a protein component of the exon junction complex, can
determine the variability in efficiency of the Nonsense Mediated Decay pathway.
Nucleic Acids Res 35: 4542–51.
49. Bateman JF, Freddi S, Nattrass G, Savarirayan R (2003) Tissue-specific RNA
surveillance? Nonsense-mediated mRNA decay causes collagen X haploinsuffi-
ciency in Schmid metaphyseal chondrodysplasia cartilage. Hum Mol Genet 12:
217–25.
50. Resta N, Susca FC, Di Giacomo MC, Stella A, Bukvic N, et al. (2006) A
homozygous frameshift mutation in the ESCO2 gene: evidence of intertissue and
interindividual variation in Nmd efficiency. J Cell Physiol 209: 67–73.
51. Holmberg C, Katz S, Lerdrup M, Herdegen T, Jaattela M, et al. (2002) A novel
specific role for I kappa B kinase complex-associated protein in cytosolic stress
signaling. J Biol Chem 277: 31918–28.
52. Kim JH, Lane WS, Reinberg D (2002) Human Elongator facilitates RNA
polymerase II transcription through chromatin. Proc Natl Acad Sci U S A 99:
1241–6.
53. Cornez I, Creppe C, Gillard M, Hennuy B, Chapelle JP, et al. (2008)
Deregulated expression of pro-survival and pro-apoptotic p53-dependent genes
upon Elongator deficiency in colon cancer cells. Biochem Pharmacol 75:
2122–34.
54. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, et al. (2010) TMEPAI, a
transmembrane TGF-beta-inducible protein, sequesters Smad proteins from
active participation in TGF-beta signaling. Mol Cell 37: 123–34.
55. Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, et al.
(2006) ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res
34: D46–55.
56. Cohen L, Henzel WJ, Baeuerle PA (1998) IKAP is a scaffold protein of the
IkappaB kinase complex. Nature 395: 292–6.
57. Pros E, Fernandez-Rodriguez J, Benito L, Ravella A, Capella G, et al. (2009)
Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.
Eur J Hum Genet 18: 614–7.
58. Viktorov IV, Savchenko EA, Chekhonin VP (2007) Spontaneous neural
differentiation of stem cells in culture of human olfactory epithelium. Bull Exp
Biol Med 144: 596–601.
59. Carmel I, Tal S, Vig I, Ast G (2004) Comparative analysis detects dependencies
among the 59 splice-site positions. RNA 10: 828–40.
60. Ibrahim EC, Hims MM, Shomron N, Burge CB, Slaugenhaupt SA, et al. (2007)
Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial
dysautonomia. Hum Mutat 28: 41–53.
61. Ule J, Ule A, Spencer J, Williams A, Hu JS, et al. (2005) Nova regulates brain-
specific splicing to shape the synapse. Nat Genet 37: 844–52.
62. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, et al. (2003)
Evaluation of candidate control genes for diagnosis and residual disease
detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase
polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia 17: 2474–86.
63. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25:
402–8.
64. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, et al. (2006) Gene
expression profiling identifies molecular subgroups among nodal peripheral T-
cell lymphomas. Oncogene 25: 1560–70.
65. Talby L, Chambost H, Roubaud MC, N’Guyen C, Milili M, et al. (2006) The
chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia
could be determined by the combined expression of CD34, SPI-B and BCR
genes. Leuk Res 30: 665–76.
66. Lopez F, Rougemont J, Loriod B, Bourgeois A, Loi L, et al. (2004) Feature
extraction and signal processing for nylon DNA microarrays. BMC Genomics 5:
38.
67. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
OE-MSCs as a Model for FD
PLoS ONE | www.plosone.org 17 December 2010 | Volume 5 | Issue 12 | e15590